For readers interested in 'in vivo' CAR-T therapies for cancer and autoimmune diseases, here's a comprehensive review from pioneers in the field nature.com/articles/s41... rdcu.be/fx2H3

In vivo chimeric antigen receptor (CAR)-T cell therapy - Nature Reviews Drug Discovery

In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo manufacturing. This Review examines emerging v...

nature.com

Johnson & Johnson announced collaboration with privately held Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases, J&J said in a statement

J&J Gains Option to Buy Sail Biomedicines for $2.6 Billion

Johnson & Johnson announced a collaboration with Sail Biomedicines to develop CAR-T therapies for immune diseases and said it now has an exclusive option to acquire the closely held company.

bloom.bg

For readers interested in mRNA therapeutics, this Review discusses progress and lessons learned from candidates in clinical trials for applications including cancer immunotherapy, genome editing and in vivo CAR-T cell therapy www.nature.com/articles/s41... rdcu.be/fxNFo

Towards mRNA therapeutics 2.0 - Nature Reviews Drug Discovery

mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzym...

nature.com

Our latest research highlight covers a paper in Nature on a novel RNA modification that could improve the characteristics of mRNA-based therapeutics www.nature.com/articles/d41...

Optimizing translation of therapeutic mRNAs

Discover the world’s best science and medicine | Nature.com

nature.com

Multispecific T-cell engagers that bind three or more targets on cancer and immune cells promise to address the shortcomings of their bispecific predecessors - find out more in this news story in our August issue www.nature.com/articles/d41...

Our August issue is live! Read about multispecific T-cell engagers for cancer, the design of small-molecule kinase inhibitors, the evolution of pharmacotherapy for obesity, safety considerations for targeted protein degraders and more here www.nature.com/nrd/volumes/...

Review @natrevdrugdiscov.nature.com Targeting T follicular helper cells for lifelong health www.nature.com/articles/s41...

Oral macrocyclic PCSK9 inhibitor secures FDA approval nature.com/articles/d41... Merck & Co.’s enlicitide has been approved to reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia

Oral macrocyclic PCSK9 inhibitor secures FDA approval

Discover the world’s best science and medicine | Nature.com

nature.com

For readers interested in drug discovery targeting GPCRs, this Review covers trends in the field: www.nature.com/articles/s41... rdcu.be/fwSqG and this Review covers opportunities from understanding of functional dynamics: www.nature.com/articles/s41... rdcu.be/fwSrj

Our latest Research Highlight covers a paper in Nature on the discovery of small-molecule inhibitors of β-arrestins, which are important transducers of signalling via G protein-coupled receptors (GPCRs) www.nature.com/articles/d41...

Small molecules stop β-arrestins

Discover the world’s best science and medicine | Nature.com

nature.com

Targeting T follicular helper cells for lifelong health nature.com/articles/s41... rdcu.be/fwdMi This new Review discusses therapeutic strategies to modulate T follicular helper (TFH) cells, which support B cell function to promote long-lasting antibody responses

Targeting T follicular helper cells for lifelong health - Nature Reviews Drug Discovery

T follicular helper (TFH) cells support B cell function to promote long-lasting antibody responses but are implicated in many diseases and undergo age-related changes. This Review explores emerging th...

nature.com

Targeting T follicular helper cells for lifelong health nature.com/articles/s41... rdcu.be/fwdMi This new Review discusses therapeutic strategies to modulate T follicular helper (TFH) cells, which support B cell function to promote long-lasting antibody responses

Targeting T follicular helper cells for lifelong health - Nature Reviews Drug Discovery

T follicular helper (TFH) cells support B cell function to promote long-lasting antibody responses but are implicated in many diseases and undergo age-related changes. This Review explores emerging th...

nature.com

Multispecific molecules are transforming pharmacotherapy - find out more about the different types in this Perspective by Raymond Deshaies, one of the pioneers in the field www.nature.com/articles/s41... rdcu.be/fvaFS

How multispecific molecules are transforming pharmacotherapy - Nature Reviews Drug Discovery

Multispecific drugs are designed to engage two or more entities to exert their pharmacological effect. This Perspective discusses how a new wave of FDA-approved multispecific molecules have been trans...

nature.com

A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails. Find out more in this news story in the July issue www.nature.com/articles/d41...

For readers interested in kinases as drug targets, this Review discusses the design of small-molecule kinase modulators, including orthosteric, allosteric and induced-proximity strategies www.nature.com/articles/s41... rdcu.be/fuTJ5

Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies - Nature Reviews Drug Discovery

Kinases represent one of the largest superfamilies of drug targets, but many members have remained notoriously challenging to drug by traditional small-molecule approaches. This Review assesses approa...

nature.com

CDK4/6 inhibitors have transformed the treatment of some forms of breast cancer. This Review in the July issue covers advances that are expanding their applications, as well as inhibitors of CDK2 that could combat resistance to CDK4/6 inhibitors www.nature.com/articles/s41... rdcu.be/fuA0Z

The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond - Nature Reviews Drug Discovery

Ten years after the first FDA approval, CDK inhibition is entering a new phase in oncology. This Review examines how combination strategies, emerging CDK2- and CDK4-selective inhibitors, and developin...

nature.com

For readers interested in AI in drug discovery, this Review in the July issue discusses the application of AI-driven approaches for therapeutic target exploration, including challenges, limitations and case studies rdcu.be/fud6U www.nature.com/articles/s41...

Target identification and assessment in the era of AI

Nature Reviews Drug Discovery - Artificial intelligence (AI) is playing an increasingly important role in drug target identification and assessment, based on its proficiency in analysing large...

rdcu.be

Brain-shuttle biologics chart new paths across the blood–brain barrier www.nature.com/articles/d41... This news story covers intensifying efforts to ferry large-molecule medicines into the brain, following the first FDA approval of an engineered biologic that overcomes delivery hurdles

Brain-shuttle biologics chart new paths across the blood–brain barrier

Efforts intensify to ferry large-molecule medicines into the brain, following the first FDA approval of an engineered biologic that overcomes delivery hurdles.

nature.com

For readers interested in pharmacotherapies for obesity, such as GLP-1-based drugs, here's a comprehensive recent review www.nature.com/articles/s41... rdcu.be/ftUQ1

The evolving landscape of obesity pharmacotherapy - Nature Reviews Drug Discovery

Incretin-based therapies are transforming the treatment of obesity and related comorbidities. This Review outlines the current landscape of obesity drug development, focusing on glucagon-like peptide ...

nature.com

FDA new drug approvals in Q2 2026 www.nature.com/articles/d41... Q2 2026 saw a rebound for novel FDA drug approvals with a total of 13, also with heavy commercial firepower thanks to products such as the first oral small-molecule GLP-1 receptor agonist

A growing pipeline of multispecific antibody therapies are in clinical trials, showcasing novel biological effects as well as potential improvements over multi-agent cocktails. Find out more in this news story in the July issue www.nature.com/articles/d41...

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development rdcu.be/ftz8C www.nature.com/articles/s41... This new Perspective discusses the value of trial simulations, presents best-practice recommendations and describes case studies of impact

mRNA technology is one of the platforms being used for n-of-1 therapies. Read about its application in this and a range of other areas such as in vivo CAR-T cell therapies and cancer immunotherapies in this Review www.nature.com/articles/s41... rdcu.be/fteeb

Towards mRNA therapeutics 2.0 - Nature Reviews Drug Discovery

mRNA technology is being applied to develop a new generation of therapies for rare and common diseases. This Review discusses insights from clinical studies on mRNA-based therapeutics, including enzym...

nature.com

For readers interested in the development of n-of-1 therapies, such as custom gene editing drugs, here's a roadmap from IRDiRC www.nature.com/articles/s41... rdcu.be/ftec1

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap - Nature Reviews Drug Discovery

A very small number of people with rare diseases caused by unique genetic variants have been treated with therapies developed specifically for them, known as N-of-1 therapies. This Review discusses ad...

nature.com

ARPA-H launches $160 million effort to develop custom gene editing drugs Program will fund seven groups over five years in hope of Baby KJ-like successes www.statnews.com/2026/07/09/a...

ARPA-H launches $160 million effort to develop custom gene editing drugs

An ARPA-H program to jump-start custom gene editing treatments was delayed by a change in administrations. Now seven labs will get sizable grants.

statnews.com

For readers interested in therapeutic strategies for chronic obstructive pulmonary disease (COPD), such as PDE3/4 inhibition - the focus of AstraZeneca's latest potential $2.1 billion deal - here's a review www.nature.com/articles/s41... rdcu.be/fs1jW

AstraZeneca Buys TQC3721 Rights for $2.1B https://www.europesays.com/britain/79279/ AstraZeneca has secured ex-China rights to TQC3721, an inhaled dual PDE3/4 inhibitor for COPD, in a deal worth…

AstraZeneca Buys TQC3721 Rights for $2.1B - Britain | EUROPESAYS.COM

AstraZeneca has secured ex-China rights to TQC3721, an inhaled dual PDE3/4 inhibitor for COPD, in a deal worth USD 200 million upfront and up to USD 2.1

europesays.com

For readers interested in claudins as therapeutic targets in cancer, including claudin 18.2 - the target of the first CAR-T cell therapy to be approved for a solid tumour - here's a comprehensive recent review www.nature.com/articles/s41... rdcu.be/fp0UQ

Targeting claudins in cancer - Nature Reviews Drug Discovery

Claudins are emerging as clinically actionable targets in cancer, exemplified by the approval of CLDN-18.2-directed therapy. This review examines the biological basis and therapeutic exploitation of c...

nature.com

CAR T cell therapy for solid cancer scores first approval in China www.nature.com/articles/d41... CARsgen Therapeutics’ claudin18.2-targeted therapy satricabtagene autoleucel has been approved for claudin18.2-positive gastric/gastroesophageal junction adenocarcinoma

Small-molecule drug candidates increasingly have limited aqueous solubility, making oral delivery challenging. This Perspective in the July issue discusses formulation approaches to mitigate solubility and dissolution rate limitations www.nature.com/articles/s41... rdcu.be/fsjUt